CVS Health remains a solid, undervalued business, despite recent underperformance, versus the S&P 500 and ongoing margin pressures. Q2/25 results showed strong revenue growth but declining operatin...

Omnicare, a CVS Health subsidiary that provides pharmacy services to skilled nursing facilities, independent and assisted living communities and other segments of the long-term care market, filed f...

WOONSOCKET, R.I. , Sept. 17, 2025 /PRNewswire/ -- CVS Health® (NYSE: CVS) has announced that its board of directors has approved a quarterly dividend of sixty-six and one-half cents ($0.665 cents) ...

Why is the healthcare industry a great place to find investments right now?

CVS' diversified model, digital push and Aetna stabilization highlight a compelling investment story.

Healthcare investing has felt like walking through quicksand this year.

CVS Health (CVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

STNE, CVS, KT, KB and USNA stand out in August for low P/B ratios and strong growth forecasts, making them value stock contenders.

CVS Health boosts 2025 EPS guidance again as Health Care Benefits and PBM businesses drive growth.

When you're building a diversified portfolio for long-term wealth, it sometimes can be easy to ignore dividend stocks in favor of high-powered growth names in the tech sector. After all, companies ...

CVS Health Corporation CVS will release earnings results for the second quarter before the opening bell on Thursday, July 31.

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced better weight-loss results and fewer side effects.

In the most recent trading session, CVS Health (CVS) closed at $58.75, indicating a -5.01% shift from the previous trading day.

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

This article upgrades my rating on CVS Health to 'Buy' as recent negative industry headlines have pressured its valuation. These negatives are fully priced in already, creating a strong GARP (growt...